Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence
Immunocompromising conditions increase the risk of invasive pneumococcal disease (IPD). Vaccine uptake in patients with these conditions may be low in part because of concerns about decreased immunogenicity and safety in these high-risk groups. We conducted a literature search to identify publicatio...
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Taylor & Francis Group
2020-11-01
|
| Edice: | Human Vaccines & Immunotherapeutics |
| Témata: | |
| On-line přístup: | http://dx.doi.org/10.1080/21645515.2020.1735224 |